Composite Artificial Skin segmentation by type distinguishes four material families that underpin product differentiation and cost structure. Silicone‑based composites dominate with an estimated 35 % share, leveraging established biocompatibility, elasticity, and scalable molding processes that suit large‑area dressings and commercial mass production. Hydrogel composites capture roughly 25 %, offering high water content, permeability, and intrinsic cooling effects that are critical for acute burn management and moist‑wound environments; their formulation complexity, however, limits price competitiveness. Bioactive polymer composites account for about 20 %, integrating growth‑factor carriers, antimicrobial agents, or cell‑adhesion motifs within polyurethane or polycaprolactone matrices, thereby commanding premium pricing for regenerative‑medicine applications. Nanofiber‑reinforced composites contribute the remaining 20 %, where electrospun nanofibers provide tunable mechanical strength and scaffold architecture that enhance cell infiltration and sensor integration, positioning them for next‑generation prosthetic‑skin interfaces. Each type’s proportion reflects its maturity, manufacturing cost, and clinical value proposition, collectively shaping the overall market dynamics and guiding R&D allocation in the next decade.
